Home / Products / Vagitocin®

Vagitocin® – clinical development on hold

Vagitocin® is a developmental pharmaceutical preparation for the treatment of vaginal atrophy. The product is based on oxytocin, a natural substance, which is produced in the body and that has been used to promote labour and breast-feeding since the beginning of the 1960ies.

Local application of Vagitocin® in the vagina has been shown to rejuvenate the vaginal mucosa. Vagitocin® is in clinical development phase 2. However, the development of Vagitocin® has been put on hold until a better understanding of its mechanism of action has been gained.

Learn more about oxytocin, vaginal atrophy and clinical development.


NOTE! Vagitocin® is not yet approved as a drug

Recent Comments

    All press releases on Spotlightstockmarket.com

    All published press releases from PEPTONIC medical is available on spotlightstockmarket.com.

    About us

    PEPTONIC Medical is an innovative Swedish pharmaceutical company developing and commercializing safe and effective products for the treatment of menopausal symptoms, such as vaginal atrophy. VagiVital® is a registered trademark of PEPTONIC Medical. The product is being commercialised for the non-prescription use for the treatment of vaginal atrophy.

    The Company was founded in 2009 and its first candidate drug product is Vagitocin® – an estrogen-free oxytocin based product for the treatment of vaginal atrophy in clinical development phase 2.

    Oxytocin has a long history of safe and effective medical use and offers an alternative to estrogen and estrogen-like acting compounds for menopausal and postmenopausal women.